透析患者高血压病研究现状(6)
[36]Kraus MA， Kansal S， Copland M， Komenda P， Weinhandl ED， Bakris GL， Chan CT， Fluck RJ， Burkart JM. Intensive hemodialysis and potential risks with increasing treatment. Am J Kidney Dis，2016，68 (5S1)：S51-S58.
[37]Liu Y， Ma X， Zheng J， Jia J， Yan T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients： a meta-analysis of randomised controlled trials. BMC Nephrol，2017，18 (1)：206.
[38]Iseki K， Arima H， Kohagura K， Komiya I， Ueda S， Tokuyama K， Shiohira Y， Uehara H， Toma S. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis： a randomized controlled trial. Nephrol Dial Transplant，2013，28 (6)：1579-1589.
[39]Agarwal R， Sinha AD， Pappas MK， Abraham TN， Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril： a randomized controlled trial. Nephrol Dial Transplant，2014，29 (3)：672-681.
[40]Matsumoto Y， Mori Y， Kageyama S， Arihara K， Sugiyama T， Ohmura H， Yakushigawa T， Sugiyama H， Shimada Y， Nojima Y， Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol，2014，63 (6)：528-536.
(收稿日期：2018-03-21)
(本文編辑：林燕薇), http://www.100md.com(刘红勇 李少敏 叶玉球 彭洪泉 胡文涛 张运强 刘迅)
[37]Liu Y， Ma X， Zheng J， Jia J， Yan T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients： a meta-analysis of randomised controlled trials. BMC Nephrol，2017，18 (1)：206.
[38]Iseki K， Arima H， Kohagura K， Komiya I， Ueda S， Tokuyama K， Shiohira Y， Uehara H， Toma S. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis： a randomized controlled trial. Nephrol Dial Transplant，2013，28 (6)：1579-1589.
[39]Agarwal R， Sinha AD， Pappas MK， Abraham TN， Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril： a randomized controlled trial. Nephrol Dial Transplant，2014，29 (3)：672-681.
[40]Matsumoto Y， Mori Y， Kageyama S， Arihara K， Sugiyama T， Ohmura H， Yakushigawa T， Sugiyama H， Shimada Y， Nojima Y， Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol，2014，63 (6)：528-536.
(收稿日期：2018-03-21)
(本文編辑：林燕薇), http://www.100md.com(刘红勇 李少敏 叶玉球 彭洪泉 胡文涛 张运强 刘迅)